CELC on Nasdaq
Celcuity Inc.
American medical laboratories services company based in Minneapolis. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerCELC on Nasdaq2
- IndustryServices-Medical Laboratories2
- HeadquartersMinneapolis, United States2
- Incorporated inDE3
- Business address16305 36Th Avenue N, Suite 100, Minneapolis, Mn 554463
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI25490070W7UU7W2SEY872
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 65442842
See how the biggest companies compare on our leaderboards
States in 2025, and approximately 42,170 breast cancer patients would die of the disease.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $145.0M | $104.2M |
| General and administrative | $27.2M | $9.1M |
| Total operating expenses | $172.2M | $113.3M |
| Loss from operations | -$172.2M | -$113.3M |
| Interest expense | -$17.1M | -$10.3M |
| Interest income | $12.3M | $11.8M |
| Other (expense) income, net | -$4.8M | $1.5M |
| Net loss before income taxes | -$177.0M | -$111.8M |
| Net loss | -$177.0M | -$111.8M |
| Net loss per share, basic | -$3.79 | -$2.83 |
| Net loss per share, diluted | -$3.79 | -$2.83 |
| Weighted average common shares outstanding, basic | 46.8M shares | 39.4M shares |
| Weighted average common shares outstanding, diluted | 46.8M shares | 39.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.10
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $165.7M | $22.5M | |
| Investments | $275.8M | $212.6M | |
| Prepaid clinical trial costs | $18.9M | $6.8M | |
| Other current assets | $5.3M | $2.7M | |
| Total current assets | $465.7M | $244.6M | |
| Property and equipment, net | $499.0K | $336.0K | |
| Operating lease right-of-use assets | $51.0K | $216.0K | |
| Other non-current assets | $349.0K | ||
| Total assets | $466.6M | $245.1M | |
| Accounts payable | $6.4M | $9.4M | |
| Accrued clinical trial costs | $16.8M | $16.7M | |
| Other accrued expenses | $20.9M | $5.5M | |
| Operating lease liabilities, current | $54.0K | $172.0K | |
| Total current liabilities | $44.2M | $31.7M | |
| Operating lease liabilities, non-current | $54.0K | ||
| Convertible debt | $195.3M | ||
| Note payable, non-current | $126.5M | $97.7M | |
| Total liabilities | $366.0M | $129.5M | |
| Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $48.0K | $37.0K | |
| Additional paid-in capital | $549.4M | $387.4M | |
| Accumulated deficit | -$448.9M | -$271.9M | |
| Total stockholders equity | $100.6M | $115.6M | $139.8M |
| Total liabilities and stockholders equity | $466.6M | $245.1M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 2.5M shares | 2.5M shares | |
| Preferred stock, shares issued | 0 shares | 317.6K shares | |
| Preferred stock, shares outstanding | 0 shares | 317.6K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 95.0M shares | 95.0M shares | |
| Common stock, shares issued | 48.2M shares | 37.1M shares | |
| Common stock, shares outstanding | 48.2M shares | 37.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $165.7M | $22.5M | |
| Investments | $275.8M | $212.6M | |
| Prepaid clinical trial costs | $18.9M | $6.8M | |
| Other current assets | $5.3M | $2.7M | |
| Total current assets | $465.7M | $244.6M | |
| Property and equipment, net | $499.0K | $336.0K | |
| Operating lease right-of-use assets | $51.0K | $216.0K | |
| Other non-current assets | $349.0K | ||
| Total assets | $466.6M | $245.1M | |
| Accounts payable | $6.4M | $9.4M | |
| Accrued clinical trial costs | $16.8M | $16.7M | |
| Other accrued expenses | $20.9M | $5.5M | |
| Operating lease liabilities, current | $54.0K | $172.0K | |
| Total current liabilities | $44.2M | $31.7M | |
| Operating lease liabilities, non-current | $54.0K | ||
| Convertible debt | $195.3M | ||
| Note payable, non-current | $126.5M | $97.7M | |
| Total liabilities | $366.0M | $129.5M | |
| Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $48.0K | $37.0K | |
| Additional paid-in capital | $549.4M | $387.4M | |
| Accumulated deficit | -$448.9M | -$271.9M | |
| Total stockholders equity | $100.6M | $115.6M | $139.8M |
| Total liabilities and stockholders equity | $466.6M | $245.1M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 2.5M shares | 2.5M shares | |
| Preferred stock, shares issued | 0 shares | 317.6K shares | |
| Preferred stock, shares outstanding | 0 shares | 317.6K shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 95.0M shares | 95.0M shares | |
| Common stock, shares issued | 48.2M shares | 37.1M shares | |
| Common stock, shares outstanding | 48.2M shares | 37.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$177.0M | -$111.8M |
| Depreciation | $167.0K | $130.0K |
| Stock-based compensation | $21.4M | $7.0M |
| Amortization of debt issuance costs and discount | $3.1M | $1.3M |
| Payment-in-kind interest | $1.1M | $1.4M |
| Non-cash operating lease expense | -$7.0K | |
| Change in accrued interest income | $630.0K | $150.0K |
| Prepaid clinical trial costs | -$12.1M | -$2.0M |
| Other current and non-current assets | -$3.0M | $2.8M |
| Accounts payable | -$3.0M | $4.3M |
| Accrued clinical trial costs | $118.0K | $10.2M |
| Other accrued expenses | $15.4M | $3.0M |
| Net cash used in operating activities | -$153.3M | -$83.5M |
| Proceeds from maturities of investments | $332.5M | $642.3M |
| Purchases of investments | -$396.3M | -$705.2M |
| Purchases of property and equipment | -$249.0K | -$250.0K |
| Net cash used in investing activities | -$64.1M | -$63.1M |
| Proceeds from employee stock purchases | $711.0K | $276.0K |
| Proceeds from exercise of common stock options | $3.5M | $770.0K |
| Proceeds from exercise of common stock warrants | $42.1M | $14.7M |
| Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively | $195.0M | |
| Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively | $27.7M | $59.2M |
| Proceeds from equity offering, net of underwriting discounts and offering costs | $91.6M | $56.3M |
| Proceeds from an ATM offering, net of issuance costs | $7.4M | |
| Payments for secondary registration statement costs | -$46.0K | -$228.0K |
| Net cash provided by financing activities | $360.6M | $138.4M |
| Net change in cash and cash equivalents | $143.2M | -$8.1M |
| Cash paid for interest | $10.3M | $7.6M |
| Cash paid for operating leases | $220.0K | $325.0K |
| Common stock warrants issued with the note payable transaction | $2.8M | $1.2M |
| Property and equipment included in accounts payable | $82.0K | $1.0K |
| Deferred financing, offering and registration statement costs included in accounts payable | $42.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Celcuity Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- Chief financial officerVicky Hahne Sep 19, 2017 to now13
Board members and other officers (9)
- Chief Science Officer, VPLance G. Laing Sep 19, 2017 to now14
- Board memberCharles R. Romp Feb 13, 2026 to now15
- Board memberPolly A. Murphy Sep 14, 2022 to now16
- Board memberLeo Furcht May 20, 2019 to now17
- Board memberRichard E. Buller Dec 5, 2019 to now18
- Board memberDavid Dalvey Sep 19, 2017 to now19
- Board memberLance G. Laing Sep 19, 2017 to now14
- Board memberMaureen Therese Cronin Sep 19, 2017 to May 20, 201920
- Board memberRichard Nigon Sep 19, 2017 to now21
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Executive Officer, Director, PromoterBrian F. Sullivan named May 26, 2022 to Sep 23, 202522
Former names
- Celcuity LLCMar 24, 2014 to Sep 15, 20173
Timeline
- Sep 15, 2017Founded Celcuity Inc. is founded2
Filings
359 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 62 major events, 128 insider forms, 54 large holders, 14 private raises, 80 other. The latest 20:
- Oct 9, 20264 EDGAR
- Oct 5, 20264 EDGAR
- Oct 5, 20263 EDGAR
- Oct 2, 20268-K EDGAR
- Sep 30, 20268-K EDGAR
- Aug 26, 20268-K EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 18, 20264 EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 13, 20268-K EDGAR
- Aug 11, 2026SCHEDULE 13G EDGAR
- Jul 16, 20264 EDGAR
- Jul 16, 2026SCHEDULE 13G EDGAR
- Jul 16, 2026SCHEDULE 13D/A EDGAR
- Jul 15, 20268-K/A EDGAR
- Jul 15, 20268-K EDGAR
- Jul 14, 2026144 EDGAR
- Jul 14, 2026144 EDGAR
- Jun 12, 20264 EDGAR
The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
49 open-market trades by officers, directors and large owners since October 2021: 6 buys and 43 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | BAKER JULIAN | Sale | 3,100,000 | $102.50 | $317.8M | Form 4 |
| May 4, 2026 | Buller Richard EDirector | Sale | 9,000 | $140.47 | $1.3M | Form 4 |
| May 4, 2026 | Dalvey DavidDirector | Sale | 25,000 | $140.68 | $3.5M | Form 4 |
| Mar 31, 2026 | Buller Richard EDirector | Sale | 3,000 | $110.27 | $330.8K | Form 4 |
| Jan 27, 2026 | Dalvey DavidDirector | Sale | 20,000 | $120.03 | $2.4M | Form 4 |
| Dec 5, 2025 | Buller Richard EDirector | Sale | 3,000 | $105.69 | $317.1K | Form 4 |
| Dec 1, 2025 | Buller Richard EDirector | Sale | 1,100 | $98.13 | $107.9K | Form 4 |
| Nov 21, 2025 | Dalvey DavidDirector | Sale | 15,000 | $100.00 | $1.5M | Form 4 |
| Nov 20, 2025 | Buller Richard EDirector | Sale | 3,900 | $96.73 | $377.2K | Form 4 |
| Sep 8, 2025 | Baker Bros. Advisors (GP) LLC | Buy | 170,100 | $56.27 | $9.6M | Form 4 |
| Jul 28, 2025 | Dalvey DavidDirector | Sale | 109,325 | $44.08 | $4.8M | Form 4 |
| Oct 23, 2024 | Buller Richard EDirector | Sale | 350 | $16.25 | $5.7K | Form 4 |
| Aug 23, 2024 | Buller Richard EDirector | Sale | 350 | $16.95 | $5.9K | Form 4 |
| Jun 21, 2024 | Buller Richard EDirector | Sale | 350 | $15.68 | $5.5K | Form 4 |
| Apr 24, 2024 | Buller Richard EDirector | Sale | 350 | $17.06 | $6.0K | Form 4 |
| Feb 21, 2024 | Buller Richard EDirector | Sale | 350 | $14.15 | $5.0K | Form 4 |
| Dec 20, 2023 | Buller Richard EDirector | Sale | 350 | $14.37 | $5.0K | Form 4 |
| Dec 15, 2023 | Dalvey DavidDirector | Sale | 2,940 | $14.57 | $42.8K | Form 4 |
| Dec 14, 2023 | Dalvey DavidDirector | Sale | 5,000 | $14.75 | $73.8K | Form 4 |
| Dec 13, 2023 | Dalvey DavidDirector | Sale | 5,000 | $14.50 | $72.5K | Form 4 |
All 49 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Bank of AmericaSCHEDULE 13G, 1 filing Aug 11, 202623
- BAKER BROS. ADVISORS LPSCHEDULE 13G, 7 filings Nov 14, 2024 to Jul 16, 202624
- RTW INVESTMENTS, LPSCHEDULE 13G, 1 filing May 15, 202625
- Growth Equity Opportunities 18 VGE, LLCSCHEDULE 13D/A, 5 filings May 24, 2022 to Mar 9, 202626
- Avoro Capital Advisors LLCSCHEDULE 13G, 1 filing Feb 17, 202627
- PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 6 filings Dec 26, 2023 to Feb 17, 202628
- Soleus Private Equity Fund II, L.P.SCHEDULE 13G/A, 2 filings Nov 14, 2024 to Feb 12, 202629
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 2 filings Jun 10, 2024 to Nov 14, 202530
- Brian F. SullivanSCHEDULE 13G/A, 4 filings Mar 4, 2022 to Nov 13, 202531
- Lance G. LaingSCHEDULE 13G/A, 4 filings Mar 4, 2022 to Nov 13, 202532
- Commodore Capital LPSCHEDULE 13G/A, 5 filings Feb 14, 2022 to Feb 14, 202533
- Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 4 filings May 18, 2022 to Feb 11, 202534
- BlackRockSCHEDULE 13G, 1 filing Feb 4, 202535
- RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 4 filings May 25, 2022 to Nov 14, 202436
- Venrock Healthcare Capital Partners III, L.P.SC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202437
- Morgan StanleySC 13G/A, 3 filings Feb 8, 2023 to Oct 7, 202438
- Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 2 filings May 25, 2022 to Feb 14, 202339
Money raised
Private offerings the company reported to the SEC on Form D.
- Oct 20, 2023Raised $50 million in a private offering of securities Form D: 2 investors so far Form D
- May 15, 2022Raised $100 million in a private offering of equity Form D: $156 million offered in all Form D
- Apr 8, 2021Raised $130 million in a private offering of debt Form D: $352.7 million offered in all Form D
- May 5, 2017Raised $2.6 million in a private offering of securities Form D: $3 million offered in all Form D
- Apr 28, 2017Raised $5.9 million in a private offering of securities Form D: $6.6 million offered in all Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7,915,792 | $828.2M | 4.2% | No change |
| Avoro Capital Advisors LLC | 3,400,000 | $355.7M | 3.2% | +25,000 |
| Rtw Investments, LP | 3,304,903 | $345.8M | 3.0% | +265,282 |
| Perceptive Advisors LLC | 3,197,200 | $334.5M | 5.2% | +70,000 |
| BlackRock, Inc. | 3,018,785 | $315.8M | 0.0% | +307,253 |
| State Street Corp | 1,955,304 | $204.6M | 0.0% | +436,599 |
| Vanguard Capital Management LLC | 1,874,137 | $196.1M | 0.0% | +91,243 |
| NEA Management Company, LLC | 1,710,561 | $179.0M | 11.3% | −575,000 |
| Soleus Capital Management, L.P. | 1,704,318 | $178.3M | 6.1% | +419,940 |
| Bank Of America Corp /de/ | 1,471,307 | $153.9M | 0.0% | +756,978 |
| Deerfield Management Company, L.P. | 1,451,014 | $151.8M | 1.9% | −262,986 |
| Morgan Stanley | 1,334,545 | $139.6M | 0.0% | −11,170 |
| Tang Capital Management LLC | 1,314,594 | $137.5M | 6.3% | +264,594 |
| Toronto Dominion Bank | 1,258,758 | $131.7M | 0.2% | +376,000 |
| Geode Capital Management, LLC | 1,111,662 | $116.3M | 0.0% | +220,592 |
| Wellington Management Group Llp | 906,595 | $94.8M | 0.0% | +477,643 |
| Goldman Sachs Group Inc | 870,449 | $91.1M | 0.0% | +105,474 |
| Point72 Asset Management, L.P. | 650,916 | $68.1M | 0.1% | +370,592 |
| Hood River Capital Management LLC | 628,411 | $65.7M | 0.5% | New |
| Alliancebernstein L.P. | 530,922 | $60.6M | 0.0% | +66,594 |
| Fmr LLC | 548,983 | $57.4M | 0.0% | +512,623 |
| Apis Capital Advisors, LLC | 538,000 | $56.3M | 5.5% | +23,000 |
| Holocene Advisors, LP | 533,147 | $55.8M | 0.1% | +163,168 |
| UBS Group AG | 520,946 | $54.5M | 0.0% | +300,783 |
| Fuller & Thaler Asset Management, Inc. | 514,396 | $53.8M | 0.1% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCelcuity Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARCelcuity Inc. filings on SEC EDGAR
- 4
- 5SEC EDGARCelcuity Inc. 10-K for fiscal 2019
- 6SEC EDGARCelcuity Inc. 10-K for fiscal 2020
- 7SEC EDGARCelcuity Inc. 10-K for fiscal 2021
- 8SEC EDGARCelcuity Inc. 10-K for fiscal 2022
- 9SEC EDGARCelcuity Inc. 10-K for fiscal 2023
- 10SEC EDGARCelcuity Inc. 10-K for fiscal 2024
- 11SEC EDGARCelcuity Inc. 10-Q for fiscal 2026
- 12SEC EDGARCelcuity Inc. 10-Q for fiscal 2026
- 13SEC EDGARVicky Hahne, Chief financial officer
- 14
- 15SEC EDGARCharles R. Romp, Board member
- 16SEC EDGARPolly A. Murphy, Board member
- 17SEC EDGARLeo Furcht, Board member
- 18SEC EDGARRichard E. Buller, Board member
- 19SEC EDGARDavid Dalvey, Board member
- 20SEC EDGARMaureen Therese Cronin, Board member
- 21SEC EDGARRichard Nigon, Board member
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39